FDA approves Roxro's Sprix
MENLO PARK, Calif. The Food and Drug Administration has approved a new nasal spray for treating pain.
Roxro Pharma announced Monday the approval of Sprix (ketorolac tromethamine), used to manage acute moderate to moderately severe pain that requires analgesia at the opioid level. The drug, which is not a narcotic, is designed for short-term pain management, lasting up to five days.
“The FDA approval of Sprix provides an important new tool for physicians treating patients with moderate to moderately severe pain,” Roxro CEO Roberto Rosenkranz said. “This is particularly significant at a time when patients and physicians have become increasingly concerned with use of narcotic pain relievers.”